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IntroductIon
Across all areas of health care, policy decision makers are in 
pursuit of what Berwick and colleagues1 have called the “triple 
aim”: i.e., improving patient experiences with care, improving 
health outcomes in the population, and managing health system 
impacts. Pursuing these goals can be challenging in the context 
of rare diseases. Challenges relate to the development of and 
access to new therapies, the generation of knowledge to under-
stand the epidemiology and natural history of the diseases, and 
the design of high-quality research needed to support effective 
and appropriate patient care.2,3 These challenges are highly rel-
evant to the field of inborn errors of metabolism (IEMs).4–6
Toward the triple aim, health system investments to 
improve and protect health for people with IEMs and other 
rare diseases include (i) secondary prevention aimed at 
early disease detection and intervention (notably newborn 
screening); (ii) study of the biological basis of rare diseases 
to inform treatment, and development of facilities for their 
diagnosis (e.g., gene and biomarker discovery for rare diseases 
and diagnostic laboratories); (iii) programs to promote the 
development of, and ensure access to, treatments that would 
otherwise be prohibitively expensive; and (iv) coordination of 
primary and specialist care, including services such as multi-
disciplinary team care and the development of regional genetic 
treatment centers (Figure 1). These system-level strategies are 
often predicated on the effectiveness of interventions at the 
level of individual patient care. For IEMs, these individual-
level interventions may include orphan drugs, medical foods, 
dietary supplements, and organ replacement. Just as health 
system–level interventions are dependent on the existence of 
effective interventions at the patient level, clinical interven-
tions by themselves cannot lead to improved outcomes unless 
patients have access to them in the context of an appropriate 
system of care (Figure 1).
Across all areas of health care, decision makers are in pursuit of what 
Berwick and colleagues have called the “triple aim”: improving patient 
experiences with care, improving health outcomes, and managing 
health system impacts. This is challenging in a rare disease context, as 
exemplified by inborn errors of metabolism. There is a need for evalu-
ative outcomes research to support effective and appropriate care for 
inborn errors of metabolism. We suggest that such research should 
consider interventions at both the level of the health system (e.g., early 
detection through newborn screening, programs to provide access to 
treatments) and the level of individual patient care (e.g., orphan drugs, 
medical foods). We have developed a  practice-based evidence frame-
work to guide outcomes research for inborn errors of m etabolism. 
Focusing on outcomes across the triple aim, this framework integrates 
three priority themes: tailoring care in the context of clinical hetero-
geneity; a shift from “urgent care” to “opportunity for improvement”; 
and the need to evaluate the comparative effectiveness of emerging 
and established therapies. Guided by the framework, a new Canadian 
research network has been established to generate knowledge that will 
inform the design and delivery of health services for patients with 
inborn errors of metabolism and other rare diseases.
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PrActIce-BAsed evIdence
The interdependency of health system and clinical care inter-
ventions points to the potential usefulness of evaluating the 
effectiveness of health care for IEMs in an integrative way. 
Currently, recommendations for providing care to patients with 
IEMs often consist of consensus guidelines developed through 
expert working groups, e.g., refs. 7 and 8 or through Delphi pro-
cesses.9 Such guidelines are directly informed by existing evi-
dence and by the opinions of experienced clinicians. However, 
they are limited by the scarcity of empirical data to support the 
effectiveness of interventions at both health system and clinical 
levels, in part, due to the challenges associated with gathering 
such evidence in the context of rare diseases.6,10 For example, 
randomized controlled trials in rare diseases require significant 
resources and multicenter collaboration11,12 yet, particularly 
with frequentist approaches, often remain underpowered to 
provide the evidence sought. Of note, traditional randomized 
controlled trials do not account well for clinical heterogeneity, 
a key feature of many IEMs.13,14 Alternative experimental and 
quasiexperimental study designs have been developed for rare 
diseases, but there are methodological challenges associated 
with each.15–17 Moreover, experimental designs do not allow the 
simultaneous evaluation of multiple interventions at the levels 
of the health-care system and individual patient care.
Observational studies may provide important knowledge 
by taking advantage of natural experiments, the opportunities 
afforded by differences in clinical practices, and/or policy-level 
interventions over time and across providers or jurisdictions, 
to investigate associations between different interventions 
and outcomes. Although such studies are susceptible to con-
founding and to bias due to differential ascertainment of cases, 
investigators can mitigate the impact of these biases by stan-
dardizing measures of key variables, achieving near complete 
case ascertainment, and evaluating the representativeness of the 
included cases. Indeed, in recognition of the need to conduct 
clinical evaluative research in real-world settings to understand 
the complex nature of care, several authors have described the 
concept of “practice-based evidence,”18,19 recently defined as 
research that “… accommodates multiple concurrent interven-
tions and patient characteristics that reflect actual clinical prac-
tice, using data from natural settings to describe the content 
and timing of treatments that are associated with better out-
comes (including patient reported outcomes) for patients with 
specific characteristics.”18
This definition of practice-based evidence is highly relevant 
to the study of IEMs. Its consideration of interventions within 
a system of care accommodates the need for an integrative 
approach, and it is broad enough to incorporate relevant out-
comes across the triple aim, including patient/family perspec-
tives and impact on the health system in addition to clinical end 
points. We suggest that a practice-based evidence approach in 
outcomes research for IEMs should not be restricted to obser-
vational research, given that randomized controlled trials and 
other experimental and quasiexperimental approaches remain 
fundamental to understanding treatment efficacy. Rather, 
observational research can provide detailed information on 
the epidemiology of IEMs and help to inform priorities for 
the development of trials. And in turn experimental methods 
can identify interventions that are efficacious in a controlled 
environment, which then need to be evaluated in an embed-
ded system of care across a range of patients and settings, to 
























Figure 1 Integrated system-level and clinical interventions for inborn errors of metabolism.
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An outcomes reseArch netWorK
A practice-based evidence approach to evaluative research for 
IEMs requires, at a minimum, the development of a network of 
practice settings with standardized collection of data capturing 
relevant outcomes and interventions.18 Such a network would 
support the strategy of multicenter collaboration and pooling 
of data that has been advocated to improve the robustness of 
research for rare diseases,6,12,20,21 incorporating the strengths typ-
ically associated with patient registries, such as complete cover-
age of patient populations (to avoid selection bias), standardized 
case definitions, and longitudinal data collection. The resources 
that are needed to develop this network and data collection sys-
tem highlight the importance of ensuring that sufficient infor-
mation is collected to answer the most important research ques-
tions while also having the flexibility to accommodate emerging 
questions in a rapidly evolving field. Thus, we suggest concep-
tualizing a practice-based evidence network not as a traditional 
registry but as an endeavor that is explicitly focused on outcomes 
evaluation, guided by a research framework to identify key ques-
tions and ensure that relevant data are captured.
In Canada, the federal government, through a Canadian 
Institutes of Health Research grant has recently invested in 
an Emerging Team to develop such a national network and 
the information system needed to support it. The Canadian 
Inherited Metabolic Diseases Research Network (CIMDRN) 
includes investigators with expertise in clinical care of patients 
with IEMs, as well as in epidemiology, health services and policy 
research, and health economics. We are supported by an advi-
sory board whose members include patient and family repre-
sentatives and scientists in related fields. All children diagnosed 
with IEMs in Canada receive care at one of 16 regional meta-
bolic treatment centers. Members of our network are located at 
nearly all these centers, which should permit complete ascer-
tainment of Canadian cases. We will collect longitudinal clini-
cal data, patient/family-reported data, and health services use 
data for all children enrolled in our research program.
The CIMDRN joins a number of other initiatives that have 
been developed to improve health care and outcomes for 
patients with IEMs and related rare diseases internationally, 
for example, the projects within the Europe-based Network for 
Genetic Metabolic Diseases Detectable by Newborn Screening 
(Metabnet),22 and several collaboratives based in North America 
(Table 1). Of note, the consortia established by the Rare Diseases 
Clinical Research Network focus on the creation of disease-
specific clinical contact registries that primarily act as tools to 
support the enrollment of patient cohorts in research studies for 
specific diseases.23–25 Other groups have focused on longitudinal 
surveillance of outcomes among patients with a broader range 
of IEMs diagnosed through newborn screening, for example, 
the Inborn Errors of Metabolism Information System developed 
by Region 4 of the Genetic and Newborn Screening Service 
Collaboratives.26 This work is now connected to the Inborn 
Errors of Metabolism Collaborative, a research project supported 
by the Newborn Screening Translational Research Network.27 
Still other groups investigate specific interventions, for example, 
the Nutrition and Dietary Supplement Interventions for Inborn 
Errors of Metabolism;28 or study the development of new or 
newly applied therapies, such as the collaborative National 
Center for Advancing Translational Sciences.29
The CIMDRN shares with these initiatives an evaluative per-
spective and, in common with registries and newborn screen-
ing long-term follow-up programs, a focus on prospective data 
collection from a complete cohort of patients. However, our 
network brings forward several innovative components. For 
example, our emphasis on the interdependence of system-level 
and clinical-level interventions and on outcomes that encom-
pass medical, patient-centered, and system perspectives (the 
triple aim) broadens our work beyond individual therapies for 
individual diseases toward the generation of knowledge that 
will generalize across IEMs and to other rare diseases. We have 
also developed a novel practice-based evidence framework 
(described below) that will serve to guide both the data we col-
lect and the research questions that our network will pursue.
A PrActIce-BAsed evIdence FrAmeWorK
The CIMDRN research framework emphasizes the full range 
of outcomes relevant to the triple aim (Figure 2), so as to make 
explicit the trade-offs that are inevitable in a rare disease envi-
ronment. For example, some interventions with modest clini-
cal benefits may be highly valued by patients and families yet 
expensive for the health-care system (e.g., enzyme replacement 
therapy). Other interventions may be relatively inexpensive 
from the health system perspective, yet experienced as bur-
densome or anxiety-provoking for patients and families (e.g., 
severe dietary restrictions may fall into this category). Studying 
these impacts simultaneously will help us to understand their 
implications with respect to the value assigned to outcomes in 
clinical and policy decisions.
We have also identified three themes that capture the types of 
evaluative research questions that are most relevant at both the 
level of individual patient care and the health system for IEMs 
and that can serve to integrate research at these levels (Figure 2). 
To demonstrate how these themes may be used to identify and 
pursue high-priority research questions both within and across 
IEMs, two illustrative case studies or examples for each theme 
table 1 Key North American examples of related initia-
tives that  support research to improve outcomes for 
inborn errors of  metabolism
Rare Diseases Clinical Research Network
 North American Mitochondrial Disease Consortium23
 Lysosomal Disease Network24
 Urea Cycle Disorders Consortium25
Regional Genetic and Newborn Screening Service Collaboratives26
Newborn Screening Translational Research Network
 Inborn Errors of Metabolism Collaborative27
Nutrition and Dietary Supplement Interventions for Inborn Errors of 
Metabolism28
National Center for Advancing Translational Sciences29
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are described below and in Figure  2. Because phenylalanine 
hydroxylase deficiency (OMIM 261600) is a more common and 
particularly well-studied IEM, one example for each theme is 
based on this disease.
theme 1: tailoring care in the context of clinical 
heterogeneity
IEMs, like many rare diseases, are frequently characterized by 
heterogeneity in clinical presentation, ranging from mild forms 
that may require no intervention to severe forms that are asso-
ciated with significant morbidity and/or mortality. For many 
IEMs, recognition of this heterogeneity has increased since their 
inclusion in newborn screening programs: their apparent preva-
lence has increased, possibly due to undiagnosed early fatal 
cases in nonscreened populations and the diagnosis of mild or 
asymptomatic cases in screened populations.30 There is uncer-
tainty about the natural history of many IEMs. Correlations 
among genotype, biochemical phenotype, and clinical symp-
toms are often weaker than predicted, highlighting the roles 
of other factors, including social characteristics, in influenc-
ing outcomes. Clinical providers face challenges in predicting 
patients’ prognoses and in developing ways to customize care. 
Heterogeneity and the need for individualized care also create 
challenges in designing effective health system investments that 
can meet the needs of a diverse population of patients and target 
therapies to those most likely to benefit. In this way, IEMs exem-
plify the challenges of personalized medicine.31 Research ques-
tions suggested by this theme, therefore, relate to identifying 
predictors of disease prognosis (including biomarkers that have 
been validated using outcomes that are important to patients), 
understanding whether and how care is tailored to account for 
differences in disease severity, and generating evidence to facili-
tate decisions about personalizing care.
Clinical heterogeneity, example 1: When does non-PKU 
hyperphenylalaninemia require treatment? Phenylalanine 
hydroxylase deficiency is associated with intolerance to 
dietary intake of the amino acid phenylalanine and results in 
a spectrum of disorders ranging from classical PKU to non-
PKU hyperphenylalaninemia (non-PKU HPA) (Figure  2).32 
Classical phenylketonuria (PKU) is usually defined as an 
untreated blood phenylalanine concentration of >1,200 µmol/l 
or low tolerance to dietary phenylalanine.32,33 Non-PKU HPA 
describes individuals whose phenylalanine levels are above 
normal (>120 µmol/l) but typically <600 µmol/l (although 
some centers define the upper limit for non-PKU HPA as <360 
µmol/l, with higher levels defined as PKU). The vast majority of 
untreated children with classical PKU show impaired cognitive 
development. The generally accepted goal of treatment, primar-
ily through dietary therapy, is reduction of blood phenylalanine 
into the therapeutic range (often defined as 120–360 µmol/l) 
and thus prevention of cognitive deficits. However, an issue of 
debate is whether patients with mild non-PKU HPA need to be 
treated.34,35 Specifically, it is unclear whether those whose blood 
phenylalanine levels are elevated but consistently below 600 
µmol/l are at risk of intellectual impairment. There is variation 
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Figure 2 A practice-based evidence research framework for inborn errors of metabolism. IEM, inborn error of metabolism; MCADD, medium-chain 
acyl-CoA dehydrogenase deficiency; MPS1, mucopolysaccharidosis 1; PKU, phenylketonuria; VLCADD, very long-chain acyl-CoA dehydrogenase deficiency.
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implications for patients, families, and the health-care system. 
For example, in Canada, costs for therapy per patient can be 
$20,000 to >$100,000/year. There is a need for research to better 
understand the association between the choice of blood phe-
nylalanine cutoff for initiation of treatment and outcomes that 
include neuropsychological development, health-related qual-
ity of life, and costs of care.
Clinical heterogeneity, example 2: What patient charac-
teristics and interventions are associated with outcomes 
among individuals with “nonclassic” medium-chain acyl-
CoA dehydrogenase deficiency or very long-chain acyl-CoA 
dehydrogenase deficiency? Medium-chain acyl-CoA dehy-
drogenase deficiency (OMIM 607008) and very long-chain 
acyl-CoA dehydrogenase deficiency (OMIM 609575) are fatty 
acid β-oxidation disorders characterized by impairments in 
energy production, particularly during times of increased 
energy demands and/or decreased dietary intake (Figure 2).37 
Patients are at risk of acute metabolic decompensation under 
conditions of metabolic stress (often caused by viral infection), 
with significant morbidity and risk of mortality.37,38 Individuals 
with very long-chain acyl-CoA dehydrogenase deficiency may 
also experience chronic sequelae (e.g., cardiac and neuromus-
cular morbidity).39 Treatment includes avoidance of fasting and 
may also include specific diet modifications and/or the use of 
supplements and medications. Newborn screening has resulted 
in the identification of a higher proportion of mild and poten-
tially asymptomatic cases for both diseases.30,40,41 For “nonclas-
sic” cases, there is uncertainty about how best to establish the 
diagnosis, predict prognosis, and manage care,9,42,43 with evi-
dence of variation in treatment practices.44 Research priorities 
include developing a better understanding of the distribution of 
outcomes (e.g., metabolic decompensation, cardiac manifesta-
tions for very long-chain acyl-CoA dehydrogenase deficiency, 
parental stress) and appropriate treatment for children with 
known high-risk disease versus those with a less certain prog-
nosis, and identifying the ways in which patient characteristics 
and interventions interact to predict outcomes in these groups.
theme 2: A shift from “urgent care” to “opportunity for 
improvement”
Traditional treatment goals for IEMs focused on prevent-
ing catastrophic outcomes such as death, irreversible neuro-
logic injury, and mental retardation. Similar to more common 
chronic diseases (e.g., diabetes, HIV), an improved understand-
ing of the biology of IEMs and corresponding development of 
new treatments has meant that many patients are surviving 
with fewer severe sequelae. New priorities include identifying 
optimal long-term outcomes and determining the intermedi-
ate indicators of disease management (e.g., validated biomark-
ers of metabolic control) that best predict such outcomes and 
can be used to monitor treatment. In parallel, there is a need 
to consider the potential for late adverse effects of interven-
tions, recognize new natural histories (revealed due to longer 
survival), and identify ineffective interventions. Thus, within 
this theme, we suggest prioritizing research that illuminates the 
appropriate goals of therapy when existing evidence suggests 
that established treatments improve but do not optimize out-
comes, explores ways to define and monitor successful disease 
management in the short-term with longer term outcomes in 
mind, and addresses the benefits and risks of therapies over a 
long-term follow-up period.
Shift, example 1: Among patients with PKU, what individ-
ual characteristics and interventions are associated with 
patient-centered outcomes beyond intelligence quotient? 
Early identification by newborn screening with initiation of 
dietary therapy has dramatically reduced the prevalence of 
mental retardation among children with PKU (Figure  2). 
However, despite measured intelligence quotient in the normal 
range, individuals with treated PKU may have less than opti-
mal psychosocial and neurodevelopmental outcomes,45–47 and 
there is little evidence regarding the impact of PKU on physical 
development.48 The goals of modern therapy, beyond prevent-
ing mental retardation, thus remain uncertain.49 Blood phenyl-
alanine levels correlate well with intelligence quotient in indi-
viduals with PKU,50 but there is a need to better understand the 
complex relationships among patient characteristics, adherence 
to dietary and other interventions, blood phenylalanine levels, 
and additional patient-centered outcomes, including executive 
function and quality of life.45,47
Shift, example 2: In patients with mucopolysacchari-
dosis 1, what are the long-term outcomes associated 
with early hematopoietic stem cell transplantation? 
Mucopolysaccharidosis 1 (Hurler disease, OMIM 607014) 
is a lysosomal storage disorder characterized by impaired 
metabolism of glycosaminoglycans, leading, in classic cases, 
to severe progressive neurocognitive, cardiorespiratory, and 
musculoskeletal impairments and shortened life expectancy 
(Figure 2).51,52 There is evidence of clinical benefit with early 
hematopoietic stem cell transplantation.52,53 Enzyme replace-
ment therapy is also used for some patients, although neu-
rodevelopmental benefit remains unclear.52 However, there 
are unresolved questions about the long-term benefits and 
safety of hematopoietic stem cell transplantation,54–56 includ-
ing the association of hematopoietic stem cell transplanta-
tion with outcomes including musculoskeletal impairment, 
neuropsychological development, child health-related qual-
ity of life, and possible late effects.
theme 3: need to evaluate comparative effectiveness of 
emerging and established therapies
Challenges in determining the effectiveness of treatments 
for IEMs relate to their rarity and heterogeneity, the complex 
nature of care, and the rapid pace of development of new treat-
ments. There is a need for ongoing evaluation of new treat-
ments while comparing them to established treatments using 
metrics capturing patient experiences, clinical outcomes, and 
health system impacts, including cost effectiveness. Linked to 
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strategic investments in patient-oriented research, comparative 
effectiveness is a current priority for both rare and common 
diseases.57 As described, multiple complementary approaches 
to comparative effectiveness research will be needed to pro-
vide the best evidence to inform care for IEMs. Priority 
research questions could therefore address the effectiveness 
and cost effectiveness of emerging therapies as compared with 
standard care, both in experimental settings and in a clini-
cal context that considers cointerventions,  patient-centered 
outcomes, and system-level policies regarding access to care. 
Because existing frameworks for assessing the effectiveness 
and cost effectiveness of interventions are unlikely to be favor-
able toward rare diseases, practice-based research within this 
theme could incorporate alternative frameworks developed 
specifically for the rare disease context.58
Comparative effectiveness, example 1: Among patients 
with PKU, how does sapropterin compare with diet ther-
apy alone in its association with a range of outcomes? An 
emerging therapy for individuals with PKU is the drug sap-
ropterin dihydrochloride (tetrahydrobiopterin) (Figure 2).59 
Evidence to date, including clinical trial data, suggests that 
a subset of individuals with PKU respond to sapropterin 
with decreases in blood phenylalanine and/or an increase 
in dietary tolerance to protein.59–64 However, there are unre-
solved questions about predictors of response to sapropterin, 
the degree of cointervention with dietary therapy needed 
(although sapropterin to date has been licensed only as an 
adjuvant therapy and not as a replacement for dietary inter-
vention), and, in particular, the association of sapropterin 
use with clinical outcomes,60,65 including neuropsychological 
outcomes, quality of life, and experiences with care. There 
is also a need for research to understand the costs of care to 
families and to the health-care system.
Comparative effectiveness, example 2: For hepatic IEMs, 
what are the comparative outcomes associated with early 
liver transplantation versus aggressive nutritional man-
agement? There is a diverse group of IEMs for which liver 
transplantation is being used in some cases because the defi-
cient enzyme for the implicated metabolic process is hepatic 
(Figure 2). For example, urea cycle defects are characterized by 
impaired excretion of nitrogen from protein catabolism, result-
ing in hyperammonemia.66 Maple syrup urine disease (OMIM 
248600) is caused by impairment of the degradation pathway for 
branched-chain amino acids and associated ketoacids.67 Patients 
with classic forms of urea cycle defects and maple syrup urine 
disease are at a high risk of metabolic decompensation during 
periods of catabolic stress and may experience additional mani-
festations including death and/or neuropsychological impair-
ment.67,68 Emerging evidence supports the effectiveness of liver 
transplantation in stabilizing metabolite levels and/or increasing 
dietary tolerance.69–72 However, there is a need to systematically 
compare the benefits and risks of early transplantation versus 
aggressive nutritional and medical interventions, which are 
also rapidly evolving.72,73 In addition to informing health care 
for hepatic IEMs, such research would inform policy debates 
regarding the prioritization of patients for liver transplantation 
and optimal use of this expensive and high-risk treatment.74
conclusion
We have described a practice-based evidence approach to out-
comes research in the field of IEMs, including a research frame-
work that can be used to identify and pursue high-priority ques-
tions related to the effectiveness of interventions at multiple 
levels. The tools we have described and that will be used by the 
CIMDRN have the potential to promote  evidence-informed 
care that is sensitive to current challenges in the care of patients 
with IEMs (for example, clinical heterogeneity, the rapid pace 
of development of new interventions) and that focuses on the 
most relevant outcomes from the perspectives of patients and 
families, providers, and health-care systems. The CIMDRN’s 
information system will initially emphasize the collection of 
existing observational data relevant to our research frame-
work. However, the network is also well positioned to initiate 
new clinical intervention studies with designs tailored for rare 
disease settings, and to collect biological samples that could 
be used to identify biomarkers for use in predicting patient 
prognosis and as surrogate end points in monitoring disease 
management. These biomarkers could be validated using out-
come information we collect across the triple aim, emphasiz-
ing end points valued by patients and families while account-
ing for important patient and environmental characteristics. 
Because the Canadian health-care system provides universal 
insurance coverage for most health services, the CIMDRN is 
also uniquely positioned to study IEMs using a combination 
of clinical and health-care administrative data, which we will 
supplement with patient- and family-reported information. 
Finally, the ethnic diversity of the Canadian population and the 
existence of a number of isolated communities will permit the 
study of disease prevalence in different population subgroups, 
which may inform the development of targeted interventions.
Ultimately, the CIMDRN aims to (i) produce clinical and 
policy guidance to improve patient experiences and out-
comes for individuals with specific IEMs and (ii) generate new 
knowledge to inform the design and delivery of health services 
for patients with a broad range of IEMs and other rare diseases 
and to provide insights into patient-centered and personalized 
care. We suggest that the ideas and framework presented here 
are also generalizable internationally and can inform other 
groups pursuing similar objectives (e.g., through the clinical 
registries and newborn screening long-term follow-up pro-
grams described in Table 1). Personalized health care has been 
defined as “…a forward-looking, consumer-centric system 
that features customized diagnostic, treatment, and manage-
ment plans based on a variety of patient factors, including 
culture, personal behaviors, preferences, family health history, 
and genetic/genomic makeup.”75 It is about identifying the 
best interventions at the appropriate times for the appropriate 
patients; this is our vision for the future of care for IEMs.
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